Bio-Pharma Launch Value Maximized Through New Product Commercialization ...( CHAPEL HILL N.C. June 13 /- Long ...),Health

CHAPEL HILL, N.C., June 13 /PRNewswire/ -- Long and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value. Leading companies are integrating commercial insights earlier and earlier into the new product process in an effort to identify and target promising compounds, reduce development cycle time, focus resources for greatest impact and increase their potential for launching a blockbuster drug.

Early-Stage Commercialization activities range from therapeutic opportunity and competitive landscape assessments to thought-leader focus groups, initial pricing studies, and pre-efficacy forecasts during pre-clinical and Phases I and II development. Global pharmaceutical companies must find ways to improve early-stage decision making and enhance product design using commercial insights to gain an overall competitive advantage in the marketplace. With these issues top of mind, Best Practices, LLC conducted primary benchmark research newly published in the report, "Best Practices in New Product Commercialization."

In a benchmarking study that included such influential companies as Abbott, Allergan, Amgen, AstraZeneca, Bayer, Eli Lilly, Genentech, GSK, Merck and Novartis, key benchmark metrics and executive insights provide a basis for informing decision-making around critical structure, resource and process planning and execution.

For a complimentary summary of the full report "Best Practices in New Product Commercialization," click on the following link http://www3.best-in-class.com/rr958.htm .

Key topic areas in the research include:

-- Early Commercialization Structure

-- Functional Involvement in Commercialization Activities

-- Cross-Functional & Regional Collaboration

-- Essential Employee Skills & Exper
'/>"/>